SBU assessed six algorithms (SR, PR, RMI, ROMA, ADNEX, LR21) for the evaluation of pre-operative ovarian cancer risk. The most frequently used algorithms in Sweden are PR and SR. General finding: SR and PR demonstrated comparable diagnostic accuracy to most alternatives for the whole population.
There is insufficient evidence to evaluate the accuracy of a screening test for metachromatic leukodystrophy (MLD) in newborns. Likewise, there is insufficient evidence to determine the efficacy of gene therapy using autologous stem cells to treat MLD.
An independent national agency, tasked by the government with assessing health care and social service interventions from a broad perspective, covering medical, economic, ethical and social aspects.
SBU conducts its projects using a systematic methodology, in line with international guidelines. Here you can find information on the different components of our methodology, together with additional links.
We have collected tools for assessing risk of bias in various types of studies as well as SBU's guidelines to assess ethical aspects of interventions.
On the 20th of October 2025, SBU was assigned its first task as co-assessor within the EU collaboration for joint clinical assessments of medicinal products and medical devices.
Swedish Agency for Health Technology Assessment and Assessment of Social Services
